Keytruda (pembrolizumab) is the first FDA approved immunotherapy drug that blocks the protein - receptor (programmed cell death - PD-1) allowing patients immune system to attack cancer.
Israel is one of the few countries allowed to use Keytruda not only for melanoma, but also as a new first-line treatment for lung cancer and for metastatic or recurrent small-cell neck or head carcinoma. Keytruda has been officially used in Israel since 2014 and has become a part of a "essential medicines package" in the following year.
The Israeli medical centers involved in the clinical trials of the drug detected improvement of treatment of melanoma without the side effects caused by traditional chemotherapy (like hair loss). The drugs also have shown promise as a “long-lasting” treatment for selected oncological diseases, but doctors continue to learn more as the drugs are used outside of clinical trials.
Tested at Sheba Medical Center, Keytruda deals with tumors using the body’s own immune system. An Israeli-tested drug was a key in helping former US president Jimmy Carter in his fight with life-threatening tumors after he was diagnosed with melanoma at the end of 2015.
The course of treatment for each patient is different. Israeli oncologists determine the number of procedures based on experience in chemotherapy and patient's general medical state.